Product/Composition:- | Etoricoxib tablets |
---|---|
Strength:- | 60 mg, 90 mg, 120 mg |
Form:- | Tablets |
Reference Brands:- | Arcoxia (EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Etoricoxib selectively inhibits the COX-2 enzyme, reducing prostaglandin synthesis responsible for pain and inflammation. It provides effective relief in rheumatoid arthritis and osteoarthritis, with a lower risk of gastrointestinal side effects compared to non-selective NSAIDs. Benefits include rapid pain reduction, improved mobility, and better safety profile for long-term use.
Etoricoxib tablets are approved in the EU for managing rheumatoid arthritis, osteoarthritis, and gout. In the EU, brands like Arcoxia are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and quality. In the US, etoricoxib is not approved by the FDA but is marketed in certain countries outside the US. Both regions require comprehensive dossiers for initial approval and ongoing pharmacovigilance. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support efficient market access for etoricoxib tablets, ensuring adherence to European standards for safe, effective pain and inflammation management.